PCN72 An EARLY Cost-Effectiveness Analysis of Xevinapant in Combination with Chemo-Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck in United States.

A Gandola,R Ait Sarkouh,P Orfanos,F Bouisset,L Licitra

doi:10.1016/j.jval.2021.04.164

PCN72 An EARLY Cost-Effectiveness Analysis of Xevinapant in Combination with Chemo-Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck in United States.

A Gandola, R Ait Sarkouh + Show 3 more

Open Access

https://doi.org/10.1016/j.jval.2021.04.164

Copy DOI

Journal: Value in Health	Publication Date: Jun 1, 2021
License type: publisher-specific-oa

Affiliation: Debiopharm (Switzerland), Fondazione IRCCS Istituto Nazionale dei Tumori

#Locally Advanced Squamous Cell Carcinoma Of The Head And Neck #Cisplatin-based Chemoradiotherapy + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

To assess the cost-effectiveness of xevinapant in combination with cisplatin-based chemoradiotherapy (CRT) compared to CRT in the treatment of patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) from the perspective of a US third-party payer.

Full Text